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Background
Immune reconstitution (IR) after hematopoietic stem cell transplantation (HSCT) reduces 
transplantation-related complications such as infection and improves HSCT outcomes. 
Methods
We retrospectively analyzed IR of lymphocyte subpopulations in 38 pediatric patients for 
hematologic malignant diseases after allogeneic HSCT from April 2006 to July 2008. 
T-cell-, B-cell-, and natural killer (NK) cell- associated antigens were assayed in peripheral 
blood by flow cytometry analysis of 5 lymphocyte subsets, CD3+, CD3+/CD4+, 
CD4+/CD8+, CD16+/CD56+, and CD19+, before and 3 and 12 months after trans-
plantation. 
Results
Reconstitutions of CD16+/CD56+ and CD3+/CD8+ lymphocytes were achieved rap-
idly, whereas that of CD3+/CD19+ lymphocytes occurred later. Age was not related to 
reconstitution of any lymphocyte subset. Total body irradiation (TBI) and anti-thymocyte 
globulin (ATG) administration were related to delayed reconstitution of total lymphocytes 
and CD3+ lymphocytes, respectively. Reconstitutions of CD3+/CD4+ lymphocytes and 
CD3+/CD8+ lymphocytes were significantly delayed in patients who received umbilical 
cord blood stem cells. In patients with chronic graft-versus-host disease (cGVHD), recov-
ery of the total lymphocyte count and CD19+ lymphocytes at 3 months post-transplant 
were significantly delayed. However, acute GVHD (aGVHD) and cytomegalovirus (CMV) 
reactivation did not influence the IR of any lymphocyte subset. Further, delayed recon-
stitution of lymphocyte subsets did not correspond to inferior survival outcomes in this 
study. 
Conclusion
We observed that some lymphocyte reconstitutions after HSCT were influenced by the 
stem cell source and preparative regimens. However, delayed CD19+ lymphocyte recon-
stitution may be associated with cGVHD.
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INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) has be-
come the established therapy for numerous hematological, 
oncological, immunological, metabolic and autoimmune dis-
orders in children [1]. Long-term host immune reconstitution 
(IR) after allogeneic HSCT (allo-HSCT) is critical because 
severe post-transplant infections, relapses, and secondary 
malignancies may be directly related to persistent immune 
defects [2]. Further, immune deficiencies, including cellular 
and antibody immunity, can last for more than a year, result-
ing in increased susceptibility to infections [2].
Various steps in the HSCT procedure can compromise 
pre-existing host immunity and IR after transplantation. 
Although treatment intensity may vary based on the disease 
and clinical condition of a patient, most treatment protocols 
destroy the recipient’s immune system almost completely. Korean J Hematol 2012;47:44-52.
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Fig. 1. Patients included in the study.
Moreover, alloreactive donor T cells co-transfused with the 
graft will eradicate any remaining recipient cells of hema-
topoietic origin. In addition, graft-versus-host disease (GVHD) 
and infection can aggravate the situation [3].
Immune recovery after HSCT has been extensively studied 
in adults [3-6]. After transplantation, monocytes are the first 
cells to engraft, followed by granulocytes, macrophages, and 
natural killer (NK) cells [7, 8]. These cell populations restore 
most of the recipient’s innate immune system, resulting in 
reduced need for antibacterial prophylaxis. In contrast to 
the rapid reconstitution of the innate immune system, recon-
stitution of lymphoid cells of the adaptive compartment is 
delayed, resulting in persistent deficits in global immunity. 
Circulating B cells may not reach normal levels for at least 
12 months after transplantation and T-cell reconstitution 
may be delayed for more than 2 years [9].
Delayed immune recovery limits the clinical efficacy of 
HSCT, resulting in increased opportunistic infections, re-
activation of latent viral and parasitic infections, chronic 
inflammation, development of autoimmunity, and high re-
lapse rate [10, 11]. Several retrospective studies conducted 
in relatively small numbers of patients have shown that 
the rate of immune reconstitution is associated with clinical 
outcomes, such as relapse, survival, and non-relapse mortality 
[12-16].
IR after HSCT is influenced by various host- and trans-
plantation- related factors, including stem cell and donor 
sources, recipient age, and method of T-cell depletion (TCD) 
[2, 3, 17]. Post-transplant factors, such as GVHD, prophylaxis 
or treatment of GVHD, antimicrobial drugs or administration 
of intravenous immunoglobulins (IVIgs) for prophylaxis, and 
donor lymphocyte infusion, can also affect post-transplant 
immune functions [2, 3, 17]. 
Although several studies have been conducted in relatively 
small numbers of patients, the data on IR after allogeneic 
HSCT in children are insufficient [11, 18-21]. Generally, 
the rate of immune function recovery after HSCT is rapid 
in children than in adults. In addition, in children, the donor 
type, stem cell source, TCD, GVHD, and/or cytomegalovirus 
(CMV) reactivation affect lymphocyte reconstitution, as in 
adults.
Here, IR, which is represented by recovery of each lym-
phocyte subset, in 38 children was analyzed. Further, the 
study analyzed potential factors affecting lymphocyte im-
mune restoration after allogeneic HSCT in children, includ-
ing age, type of donor, source of hematopoietic stem cells, 
GVHD and/or CMV reactivation. In addition, correlations 
between reconstitution of each lymphocyte subset and HSCT 
outcomes such as overall survival, relapse, and/or event-free 
survival were analyzed. 
MATERLIALS AND METHODS
1. Patients
During April 2006 - July 2008, 44 children underwent 
45 HSCT for hematologic malignancies in the Department 
of Pediatrics at the Asan Medical Center. Among the 44 
patients, the IR data for the following patients were not 
included in the study: (1) Three patients who died of treat-
ment-related complications before 3 months post-transplant; 
(2) Two patients, both of whom received their first trans-
plants before 2006, who received their second transplants 
for relapsed diseases; (3) One patient who received 2 HSCTs 
because of disease relapse 7 months after the first transplant; 
in this case, the IR data for the second HSCT was not included; 
and (4) One patient who received cord blood stem cell and 
experienced secondary engraft failure after ganciclovir treat-
ment against CMV reactivation. In summary, 38 recon-
stitution data from 38 patients who survived for more than 
100 days after HSCT were included in the analysis of lympho-
cyte reconstitution at 3 months post-transplant (Fig. 1).
For analyzing lymphocyte reconstitution at 1 year post- 
transplant, the data for 7 patients who experienced relapse 
before 1 year post-transplant and 5 patients who died during 
three months - 1 year post-transplant were not available; 
therefore, the reconstitution data of only 26 patients were 
included (Fig. 1). These 26 children remained disease-free 
and were followed up for at least 1 year post-transplant.
The patient characteristics are summarized in Table 1. 
2. Transplantation procedures
The preparative regimen for individual transplant varied 
according to the disease, donor type, and/or stem cell source 
(Table 2). All patients received high-dose myeloablative Korean J Hematol 2012;47:44-52.
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Table 1. Patient characteristics.
N (%)
HSCT period Apr 2006-July 2008
Number of patients              38 (100)
Age at HSCT Median 101.5 mo (10-195 mo) 
Follow-up Median 25.5 mo (12-37 mo)
Sex
    M            24 (63)
    F            14 (37)
Diagnosis
    ALL            12 (32)
    AML            23 (61)
    CML            1 (2)
    MDS            2 (5)
Conditioning regimen
    TBI (+)            11 (29)
    ATG (+)              8 (21)
Type of donor
    HLA-matched related            10 (26)
    HLA-matched unrelated (8/8)            10 (26)
    HLA-mismatched unrelated (≤7/8)            18 (48)
Stem cell source
    Bone marrow (BM)            14 (37)
    Peripheral blood stem cell (PBSC)            16 (42)
    Cord blood (CB)              8 (21)
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute 
myeloid leukemia; CML, chronic myeloid leukemia; MDS, my-
elodysplastic syndrome; HLA, human leukocyte antigen; TBI, total 
body irradiation; ATG, anti-thymocyte globulin.
Table 2. Summary of HSCT procedures and outcomes.
Diagnosis
No. 
patients
Type of 
HSCT
Conditioning 
regimen
GVHD prophylaxis Complications Follow-up
ALL 12    BMT (N=5) BU, CY (N=2)
TBI, CY (N=3)
 CSA, MTX (11/11) aGVHD≥II 6/12
cGVHD
a) 9/12
AW 7/12
DOD 1/12
PBSCT (N=6) BU, CY (N=1)
TBI, CY (N=5)
CMV 4/12
Relapse 2/12
Died 4/12
(3 GVHD and sepsis,
    CBT (N=1) BU, CY, ATG (N=1) CSA, MMF (1/1)  1 IPS and ARDS)
AML 23    BMT (N=8) BU, CY (N=7)
TBI, CY (N=1)
 CSA, MTX (17/17) aGVHD≥II 8/23
cGVHD
a) 9/23
AW 17/23
DOD 4/23
PBSCT (N=9) BU, CY (N=9) CMV 5/23 Died 2/23
    CBT (N=6) BU, FLU, ATG (N=4)
BU, CY, ATG (N=1)
TBI, CY, ATG (N=1)
CSA, MMF (5/6)
 CSA, MPD (1/6)
Relapse 5/23 (2 GVHD and sepsis)
CML   1    BMT (N=1) BU, CY (N=1)  CSA, MTX (1/1) AW 1/1
MDS   2 PBSCT (N=1) TBI, CY, ATG (N=1)  CSA, MTX (1/1) aGVHD≥II 1/2 AW 1/2
    CBT (N=1) TBI, FLU, CY (N=1) CSA, MMF (1/1) cGVHD
a) 1/2
CMV 1/2
Died 1/2 (GVHD and sepsis)
Total 38    BMT (N=14)
PBSCT (N=16)
    CBT (N=8)
a)Limited or extensive.
Abbreviations: HSCT, hematopoietic stem cell transplantation; AW, alive and well; DOD, died of disease; ALL, acute lymphoblastic leukemia; 
AML, acute myeloid leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; BMT, bone marrow transplantation; PBSCT,
peripheral blood stem cell transplantation; CBT, cord blood stem cell transplantation; BU, busulfan; CY, cyclophosphamide; TBI, total body 
irradiation; FLU, fludarabine; ATG, anti-thymocyte globulin; CSA, cyclosporin A; MTX, methotrexate; MMF, mycophenolate mofetil; MPD, 
methyl prednisolone; IPS, idiopathic pneumonia syndrome; ARDS, acute respiratory distress syndrome.
chemotherapy.
Prophylaxis for GVHD for most patients consisted of a 
short course of methotrexate (MTX) and cyclosporine A 
(CsA). All patients who had cord blood stem cell trans-
plantation (CBT) received CsA and mycophenolate mofetil 
(MMF), except 1 patient who received CsA and methyl pre-
dnisolone (MPD).
The first-line treatment for acute GVHD (aGVHD) was 
high-dose MPD. Further, if a favorable response to the MPD 
therapy was not evident within 5 to 7 days, the second-line 
medication was administered on a case by case basis.
All patients received prophylactic antibiotics until neu-
trophil engraftment was observed, and received antifungal 
agents for 75 days post-transplant unless GVHD developed, 
which required additional immunosuppressive treatment. A 
prophylactic dose of acyclovir was administered for 100 days 
or 1 year depending on the recipient’s immunity to varicella. 
CMV reactivation, which is presence of the nuclear CMV-re-
lated antigen pp65 in the blood, was preemptively treated 
with ganciclovir and/or foscavir.
All patients received 500 mg/kg prophylactic IVIgs alter-
nate weeks from 7 days post-transplant until 90 days; further, 
every 4 weeks until 180 days post-transplant, as long as 
the patient was alive and there was no concern of volume 
overload for IVIg infusion.
HSCT procedures and survival outcomes are summarized Korean J Hematol 2012;47:44-52.
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Table 3. Summary of lymphocyte reconstitution in all patients.
Lymphocyte 
subgroup
Pre-HSCT (N=38) 3 mo post-HSCT (N=38) 12 mo post-HSCT (N=26)
Absolute 
count 
median
/mm
3 
(range)
Median 
SDS 
(range)
No. of 
patients 
with 
normal 
values 
(%)
Absolute 
count 
median 
/mm
3 
(range)
Median 
SDS 
(range)
No. of 
patients 
with 
recovery 
(%) 
Absolute 
count 
median
/mm
3 
(range)
Median 
SDS 
(range)
No. of 
patients 
with 
recovery 
(%)
Total  786  -1.60      7 1,355  -1.23 21 2,569  -0.037 23 
lymphocytes  (224 to 4,071) (-2.96 to 2.56) (18) (196 to 3,538) (-2.86 to 1.81) (55) (957 to 9,179) (-2.60 to 3.78) (88)
CD3+  481  -1.43  11     797  -1.10  18  1,556  -0.450  23 
lymphocytes (132 to 3,131) (-2.55 to 2.89) (29) (25 to 2,401) (-2.75 to 0.79) (47) (362 to 5,930) (-1.75 to 7.98) (88) 
CD3+/CD4+ 240  -1.39  10     244  -1.48    5     629  -0.631  22 
lymphocytes (45 to 1,702) (-2.57 to 3.56) (26) (21 to 530) (-2.66 to 0.084) (13) (165 to 1,435) (-1.89 to 1.47) (85)
CD3+/CD8+ 273  -1.08  17     475    -0.559  29     777  -0.079  26 
lymphocytes (50 to 1,240) (-2.15 to 3.80) (45) (4 to 1,878) (-2.34 to 2.95) (76) (123 to 4,819) (-1.52 to 14.9) (93)
CD16+/CD56+ 150    -0.537  24     227    -0.254  35     382  -0.126  26 
lymphocytes (4 to 751) (-1.24 to 1.20) (63) (17 to 1,241) (-1.22 to 3.00) (92) (37 to 2,396) (-0.904 to 10.7) (93)
CD19+     6  -1.61    1       66  -1.21    6     471  -0.578  18 
lymphocytes (0 to 513) (-2.40 to 2.14) (3) (1 to 1,731) (-2.39 to 2.12) (16) (62 to 2,666) (-1.99 to 2.66) (69)
Abbreviation: SDS, standard deviation score; this was calculated on the bases of the reference values from Kim et al. (2001) [23].
in  Table 2.
3. Immunophenotypic studies
T-cell-, B-cell-, and NK- associated antigens in the periph-
eral blood (PB) were evaluated using fluorescence-activated 
cell sorter (FACS) system, after which we analyzed 5 lympho-
cyte subsets, namely CD3+, CD3+/CD4+, CD3+/CD8+, 
CD16+/CD56+, and CD19+ cells. The sequential analysis of 
lymphocyte recovery was performed at 3 time points: 
pre-transplant, 3 months post-transplant, and 12 months 
post-transplant. The absolute number of each lymphocyte 
subpopulation was calculated from the total number of PB 
lymphocytes. Owing to low total lymphocyte counts (TLC) 
in the early immune recovery phase after HSCT, we calcu-
lated the absolute counts of lymphocyte subsets and not 
their relative frequencies. These results were then related 
to age-matched reference values for healthy children [22]. 
A lymphocyte subset was considered immunophenotypically 
reconstituted or normalized if the absolute count of a lym-
phocyte subset surpassed fifth percentile for age-matched 
healthy population.
4. Statistical analysis
The standard deviation scores (SDSs) based on reference 
values for Korean children [23] were used as quantitative 
descriptors for each lymphocyte subpopulation, because 
these scores reflected the normal variations of lymphocyte 
counts according to age and sex.
Patients were subdivided according to their age, type of 
donor, type of stem cell source, CMV reactivation, and/or 
GVHD (grade ≥II). The SDSs of each immunophenotype 
was compared to detect statistically significant differences 
using Mann-Whitney’s rank-sum test for 2 groups and 
Kruskal-Wallis variance analysis for more than 2 groups.
In addition, patients were divided into 2 groups: one with 
recovery of each lymphocyte subpopulation achieved at 3 
months post-transplant and the other without recovery. 
Patient characteristics, conditions on transplant, complica-
tions, and outcome parameters, such as relapse, event, and 
survival in the 2 groups were compared using chi-square 
or Fischer’s exact test. The probabilities of overall survival 
(OS), relapse-free survival (RFS), and event-free survival 
(EFS) at 2 years after HSCT for each group were estimated 
using Kaplan-Meyer method, where OS was defined as the 
time between date of HSCT and date of death/latest fol-
low-up; RFS, the time between date of HSCT and date of 
diagnosis of relapse; and EFS, the time between date of HSCT 
and date of death, loss during follow-up, or diagnosis of 
relapse, whichever occurred first. Statistical differences were 
analyzed using Mann-Whitney’s rank-sum test. 
All reported P-values were 2-sided probability levels and 
those less than 0.05 were considered statistically significant. 
Statistical analyses were performed using Statistical Package 
for the Social Sciences (SPSS) 14.0 software.
RESULTS
1. Lymphocyte reconstitution in all patients
The lymphocyte recovery patterns in all 38 HSCTs are 
shown in Table 3.
CD19+ lymphocyte reconstitution was the slowest, fol-
lowed by CD4+ lymphocytes. At 3 months post-transplant, 
only 16% of patients had recovered their CD19+ cell counts 
above the fifth percentile value for age-matched healthy 
population, and only 69% of patients who survived for more 
than 1 year after HSCT without disease relapse at 12 months 
post-transplant. CD3+/CD4+ lymphocyte counts showed the Korean J Hematol 2012;47:44-52.
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lowest median SDS at 3 months post-transplant, but recon-
stitution was achieved in 85% of patients without relapse 
for more than a year. 
Conversely, rapid recovery was observed for CD16+/ 
CD56+ and CD3+/CD8+ lymphocytes at 3 months post-trans-
plant in 92% and 76% of patients, respectively.
2. Potential factors influencing lymphocyte reconstitution
The factors potentially influencing fast IR were age, con-
ditioning regimen, donor type according to the level of 
HLA-matches, source of stem cells, GVHD, and/or CMV 
reactivation
1) Age
Patients were divided into 2 subgroups, patients below 
10 years of age (N=23) and those aged above 10 years (N=15). 
The lymphocyte subtype reconstitution in both the groups 
showed no statistical differences with regard to the dis-
tribution of sex, disease, TBI, and/or ATG in the preparative 
regimen, donor type, and stem cell source; however, the 
younger group showed more numbers of CD34+ cells (P= 
0.049).
The younger patient group showed significantly high SDS 
for all lymphocyte subtypes and TLC at pre-transplant (data 
not shown). However, at 3 months and 12 months post-trans-
plant, no statistical difference in SDS for any lymphocyte 
subset was observed, with the exception of CD3+/CD4+ lym-
phocytes at 3 months post-transplant, for which younger 
patients showed a significantly high SDS (P=0.010). Nonethe-
less, the proportion of recovered patients in each group was 
not statistically different for any lymphocyte subset (Table 
4).
2) TBI in conditioning regimen
There were no statistical differences in any other trans-
plant- related conditions between the group of patients who 
received TBI and those who did not. aGVHD prevalence 
was not related to TBI but chronic GVHD (cGVHD) devel-
oped more frequently in patients who received TBI (P= 
0.013).
The TBI group showed low SDSs for all lymphocyte subsets 
before HSCT, but the values obtained were not statistically 
different. This tendency persisted after transplant, but only 
SDS of TLC at 3 months post HSCT showed statistical sig-
nificance (P=0.026).
The proportion of patients who achieved normal TLC 
at 3 months after HSCT was significantly low in the TBI 
group (P=0.037), but no other lymphocyte reconstitution 
showed differences between the TBI and non-TBI group 
(Table 4).
3) ATG in conditioning regimen
Eight patients were administered ATG, of whom 7 received 
umbilical cord blood stem cells (UCB) (P=0.035, for stem 
cell source between ATG group and non-ATG group). At 
3 months post-transplant, the SDSs of CD16+/CD56+ and 
CD19+ lymphocytes were significantly low in the ATG group 
(P=0.029 and ＜0.001, respectively), and the proportion of 
patients showing CD3+ lymphocyte reconstitution was sig-
nificantly low in the ATG group (P=0.045;  Table 4). At 
12 months post-transplant, patients in the ATG group showed 
similar SDSs for all lymphocyte subsets and TLC. IR between 
ATG and non-ATG groups did not differ at 12 months 
post-transplant (Table 4).
4) Donor type and stem cell source
The IR differences were also analyzed according to the 
donor type. Patients were divided into 2 subgroups: one 
with complete donor HLA match and the other with partial 
donor HLA mismatch, regardless of kinship. Further, there 
were no other significant differences in conditions between 
the 2 groups. Although there were a high number of aGVHD 
patients in the HLA-mismatched group, no significant differ-
ences were observed between the 2 groups for any lympho-
cyte subsets, except for a high CD3+/CD8+ lymphocyte re-
covery in the HLA-matched group (P=0.007;  Table 4).
The SDS of each lymphocyte subset showed no significant 
difference among the 3 stem cell sources [bone marrow (BM), 
PB stem cells (PBSC), and UCB], except for CD3+/CD4+ 
and CD3+/CD8+ lymphocytes at 3 months post-transplant, 
where the UBC group showed the lowest SDS (P=0.050 
and 0.014, respectively). The IR achievement for both 
CD3+/CD4+ and CD3+/CD8+ lymphocytes was both high 
and statistically significant in the PBSC group (P=0.007 and 
0.027, respectively; Table 4). However, at 12 months post- 
transplant, the proportion of patients who achieved recon-
stitution of any specific lymphocyte subset showed no stat-
istical significance among the 3 groups (Table 4).
5) GVHD
At 3 months post-transplant, the SDS of CD19+ lympho-
cyte was significantly low in the aGVHD group (P=0.001). 
In addition, few patients in the aGVHD group showed total 
lymphocyte or CD19+ lymphocyte reconstitution at 3 months 
post-transplant, but the numbers were not statistically sig-
nificant (Table 4).
The prevalence of cGVHD was significantly high in the 
TBI group (P=0.013). The proportion of the patients who 
achieved IR at 3 months post-transplant was significantly 
lower in the cGVHD group than in the non-cGVHD group 
(TLC and CD19+ lymphocyte, P=0.008 and 0.020, re-
spectively; Table 4). In addition, only cGVHD, and not TBI 
was found to be independently related to delayed IR of 
total lymphocyte during multivariate analysis (P=0.009).
6) CMV reactivation
The SDSs of each lymphocyte subset did not differ with 
respect to CMV reactivation at 3 months post-transplant. 
However, at 12 months post-transplant, the SDS of CD3+/ 
CD8+ lymphocytes was significantly high in the CMV re-
activation group (P=0.039). IR of each lymphocyte subset 
did not differ between the 2 groups.
3. Comparisons of survival according to the reconstituted 
lymphocyte subset
The RFS, EFS, and OS were analyzed for all patients who 
survived more than 100 days after HSCT.
The probability of RFS at 48 months after HSCT for all 
patients was 75.1±8.1%. At any time point and for all lympho-
cyte subsets, no statistically significant difference in RFS Korean J Hematol 2012;47:44-52.
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was observed between patients who achieved a specific lym-
phocyte reconstitution and those who did not.
The probability of EFS at 48 months post-transplant for 
all patients was 61.1±8.4%. At 3 months post-transplant, 
higher EFS was observed in patients with CD3+ lymphocyte 
reconstitution than those without reconstitution; however, 
the P-value was not significant (77.8% vs 48.5%; P=0.09). 
CD3+/CD4+, CD3+/CD8+, CD16+/CD56+, and CD19+ lym-
phocyte reconstitution at months post-transplant was not 
related to change in EFS.
The probability of OS at 48 months post-transplant for 
all patients was 70.3±7.5%. There were no statistical differ-
ences in OS between the patients with reconstitution and 
those without reconstitution for any lymphocyte subset at 
3 months after HSCT.
DISCUSSION
We analyzed IR of lymphocyte subpopulations after allo-
geneic HSCT in 38 patients with 38 HSCTs for hematological 
malignancies. Recovery in all patients, which was measured 
as IR values above the fifth percentile of age-matched refer-
ence values [22], was achieved most patients who survived 
more than 1 year without relapse. Notably, 92% of patients 
achieved IR of CD16+/CD56+ lymphocytes at 3 months 
post-transplant. However, IR for CD19+ cells was achieved 
in only 69% at 1 year post-transplant. In addition, CD3+/ 
CD8+ lymphocyte recovery occurred faster than CD3+/CD4+ 
lymphocyte recovery. These results showed that each lym-
phocyte subset reconstitution develops at different rate, 
which was similar to that described in previous studies [7, 
8]. Further, long-term imbalance between recovery of 
CD3+/CD4+ helper T cells and CD3+/CD8+ suppressor/cyto-
toxic T cells is a well-known phenomenon [24, 25].
Storek et al. [26] showed that advanced age, graft type 
(BM versus PBSC), CD34 cell dose, TBI in the conditioning 
regimen, and aGVHD and cGVHD impaired T-cell recon-
stitution in adults following T-cell replete HSCT. Studies 
at Memorial Sloan-Kettering Cancer Research Center 
(MSKCC) showed that age above 19 years and administrating 
ATG to prevent graft rejection following TCD related or 
unrelated BMT adversely impacted CD4+ T cell recovery 
and acquisition of normal T-cell function [27, 28]. Other 
studies also showed that adult recipients of TCD unrelated 
BM transplantation (BMT) experienced prolonged and pro-
found CD3+, CD4+, and CD8+ T-cell deficiencies than in 
young recipients of unrelated BMT and adult recipients of 
related BM. Additionally, they showed significantly in-
creased risk of life-threatening opportunistic infections and 
that the rate of recovery of CD4+ T cells correlated with 
the risk of developing these infections [29, 30]. 
We identified some factors influencing a specific lympho-
cyte IR.
Many studies have shown age as an important factor influ-
encing IR, even in children [11, 20]. However, we did not 
observe age to affect the recovery of any lymphocyte subset. 
This might be partly because the fifth percentiles of absolute 
counts of CD3+/CD4+ T lymphocyte counts and other lym-
phocyte subsets are high in young children, which shows 
an increased “recovery threshold” with lower age [20]. The 
comparatively slow recovery of CD4+ T lymphocytes shown 
in this study was consistent with that shown in other studies 
on children [11, 20]; however, our results did not agree 
with that shown by Mackall et al. [25], in which thymus- 
dependent reconstitution of CD3+/CD4+ lymphocytes after 
cytotoxic therapy was delayed in adults than in children. 
CD8+ suppressor/cytotoxic lymphocytes rapidly recovered 
to normal absolute counts after allogeneic HSCT in children, 
despite potential damage to the thymus by myeloablative 
therapy [24, 28].
De Vries et al. [20] reported no significant difference in 
the recovery rate of main lymphocyte subpopulations be-
tween HLA-identical and HLA-matched unrelated trans-
plants, which is consistent with that of our study, except 
for delay in CD8+ lymphocyte reconstitution in the HLA- 
mismatched group.
Stem cell source also influences the rate of lymphocyte 
reconstitution. Ottinger et al. [31] reported that IR of naïve 
(CD4+/CD45RA+) and memory (CD4+/CD45RO+) helper T 
cells and CD19+ B cells was faster in PBSC transplant (PBSCT) 
recipients than in BMT recipients. Morbidity and mortality 
because of opportunistic infections was high in CBT recipi-
ents, because of delayed or disturbed IR [32-34]. In this 
study, compared to BMT or PBSCT recipients, CBT recipients 
showed significantly delayed CD4+ and CD8+ T cell recon-
stitutions at 3 months post-transplant. Moreover, all 6 pa-
tients who achieved CD4+ lymphocyte recovery at 3 months 
post-transplant were PBSCT recipients. No differences in 
IR of CD8+ and CD16+/CD56+ lymphocytes were observed 
with regard to the stem cell source, which is in agreement 
with other studies [31, 32].
The composition of a preparative regimen is known to 
influence IR [3, 26]. All patients included in this study re-
ceived various myeloablative conditioning. TBI was per-
formed for 11 patients, of which 8 were ALL patients. A 
delayed TLC recovery was observed in these patients at 3 
months post-transplant, than in non-TBI patients. There 
were no differences in IR according to the type of leukemia 
(lymphoid vs. myeloid; data not shown). Eight patients re-
ceived ATG conditioning, of which 7 were CBT recipients. 
The CD3+ recovery in these patients was significantly lower 
than that in patients without ATG conditioning. 
Immunophenotypic assessment showed that aGVHD has 
little impact on the rate of lymphoid reconstitution [2, 35]. 
However, aGVHD is a major predictor of cGVHD and both 
have been shown to negatively impact recipient thymic func-
tion, even after curing cGVHD [36]. Our study showed sim-
ilar results, in that aGVHD was not related to IR of any 
lymphocyte subset. However, cGVHD patients showed sig-
nificantly delayed total lymphocyte recovery and CD19+ 
lymphocyte IR at 3 months post-transplant. 
We also noted an improved EFS tendency in patient with 
CD3+ lymphocyte reconstitution at 3 months post-trans-Korean J Hematol 2012;47:44-52.
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plant. However, impaired reconstitution of any lymphocyte 
subset examined in this study could not be correlated to 
impaired survival.
In conclusion, the IR of different lymphocyte subsets oc-
curred at different rates after allogeneic HSCT in children. 
Further, although CD16+/CD56+ lymphocyte reconstitution 
was achieved in most patients by 3 months post-transplant, 
CD3+/CD4+ and CD19+ lymphocytes showed delayed recon-
s t i t u t i o n .  I n  a d d i t i o n ,  s t e m  cell source, TBI and/or ATG 
conditioning, and cGVHD were found to be related to de-
layed recovery of specific lymphocyte subset. However, im-
paired reconstitution of any lymphocyte subset examined 
in this study was not correlated to impaired survival outcome. 
Future studies involving large number of patients and entail-
ing functional analysis of reconstituted lymphocyte subsets 
are necessary to confirm our findings.
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